Figure S10 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Variation of SIP in the overall ICI cohort and in progressing and non-progressing patients (A). Variation of immunosenescence markers (CD28 absence, CD57 expression, KLRG1 expression) on CD4 and CD8+ T-cells and variation of circulating TEMRA, naïve or TC1 CD8+ T-cells in the overall ICI cohort and in progressing and non-progressing patients (B)